Kalydeco (Ivacaftor) Ivacaftor Kalydeco
Ivacaftor (trade name Kalydeco, developed as VX-770) is a drug approved for patients with a certain mutation
of cystic fibrosis, which accounts for 4–5% cases of cystic fibrosis.[1][2] Ivacaftor was developed by Vertex
Pharmaceuticals in conjunction with the Cystic Fibrosis Foundation
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View